Elite Pharmaceuticals(OTC) ELTP

Elite Pharmaceuticals makes generic medicines for pain, weight loss, and mental health. Its products help patients manage chronic conditions and everyday health needs. The company supplies pharmacies, hospitals, and healthcare providers across the United States.

Pills, Powders, and Profits: What Elite Sells

• Generic Pharmaceuticals (vast majority of revenue): Affordable versions of brand-name drugs for pain, weight loss, and mental health, sold to pharmacies and hospitals.
• Contract Manufacturing: Produces controlled-release medicines for other companies, focusing on pain, allergy, and infection treatments.
• Branded Pharmaceuticals (0% of revenue, paused): Previously developed new drugs under its own name, but this activity is currently on hold.
• Abuse-Deterrent Opioids: Developing painkillers designed to reduce misuse, though these are not yet on the market.

Growth Spurts and Strategic Moves

• Acquired generic drug rights from Nostrum Laboratories in June 2024, expanding its pain and addiction treatment portfolio.
• Launched generic Percocet (pain relief) in April 2025, adding a key product line.
• Introduced generics for Vyvanse (ADHD) in December 2024, Methotrexate in August 2024, and Acetaminophen/Codeine in October 2024.
• Shifted from licensing to direct sales under the Elite label, aiming for higher margins and more control.

Why Elite Stands Out (Without Standing on a Soapbox)

Elite specializes in hard-to-make, controlled-release generic drugs, which face fewer competitors. Its facility is registered with the U.S. Drug Enforcement Administration, allowing it to handle controlled substances. The company’s broad product range helps reduce risk from any single drug or market.

Five Things You Need to Know

• Revenue was $40 million in Q1 fiscal 2026, up 113.9% from Q1 fiscal 2025.
• Gross margin rose to 68% in Q1 fiscal 2026, up from 45% in Q1 fiscal 2025.
• Operating income reached $21.7 million in Q1 fiscal 2026, up 461.6% year-over-year.
• Net loss was $6 million in Q1 fiscal 2026, mainly due to a $22.1 million non-cash expense.

Bottom Line

Elite has grown quickly by expanding its generic drug lineup and shifting to direct sales. Its focus on complex generics and contract manufacturing supports a diverse, adaptable business model.